Department of Pathology, Microbiology, and Immunology, Center for Vector Borne Diseases, School of Veterinary Medicine, University of California, Davis, USA.
Vector Borne Zoonotic Dis. 2011 Jun;11(6):683-9. doi: 10.1089/vbz.2010.0150. Epub 2011 Feb 1.
Previous studies have demonstrated reduced replication of the cell culture-adapted Dengue-2 virus (DENV-2) vaccine candidate, primary dog kidney (PDK)-53, compared with the parental DENV-2 strain, 16681, in C6/36 cells. Various DENV-2 mutants incorporating PDK-53 substitutions singly and in combination into the 16681 genetic backbone were used to identify the genetic basis for impaired replication of the vaccine candidate in vitro in Aedes aegypti cell culture (Aag2 cells) as well as the reduced in vivo infectivity and transmissibility within Ae. aegypti infected by intrathoracic inoculation. 5' untranslated region (UTR-c57t) and nonstructural protein 1 (NS1-G53D) mutations were required to completely attenuate in vitro replication. In contrast, incorporation of the PDK-53-specific NS3-250V mutation into the 16681 virus resulted in reduced replication in mosquitoes but had no effect on in vitro replication. Further, reversion of the PDK-53 NS3-250 site to that of the wild-type 16681 virus (NS3-V250E) failed to increase either in vitro or in vivo replication. Intrathoracic inoculation of Ae. aegypti with mutants containing the PDK-53 NS1 substitution exhibited in vivo replication indistinguishable from the parental PDK-53 virus, implicating this mutation as the dominant determinant for impaired mosquito replication of the PDK-53 candidate; however, further attenuation of in vivo replication was magnified in mutants including the additional 5'UTR-c57t mutation.
先前的研究表明,与亲本登革热 2 型病毒(DENV-2)株 16681 相比,细胞培养适应株 PDK-53 对 C6/36 细胞中的细胞培养适应株 DENV-2 病毒(DENV-2)候选疫苗的复制能力降低。各种将 PDK-53 取代物单独或组合并入 16681 遗传背景的 DENV-2 突变体,用于鉴定候选疫苗在埃及伊蚊细胞培养(Aag2 细胞)中的体外复制能力受损的遗传基础,以及通过胸内接种感染埃及伊蚊时的体内感染力和传染性降低。5'非翻译区(UTR-c57t)和非结构蛋白 1(NS1-G53D)突变需要完全减弱体外复制。相比之下,将 PDK-53 特异性 NS3-250V 突变体掺入 16681 病毒中会导致在蚊子中的复制能力降低,但对体外复制没有影响。此外,将 PDK-53 NS3-250 位点回复为野生型 16681 病毒(NS3-V250E)的 PDK-53 并没有增加体外或体内复制。通过胸内接种含有 PDK-53 NS1 取代的突变体的埃及伊蚊,在体内复制与亲本 PDK-53 病毒无明显差异,表明该突变体是 PDK-53 候选疫苗对蚊子复制能力降低的主要决定因素;然而,包括额外的 5'UTR-c57t 突变在内的突变体进一步降低了体内复制能力。